CN113637064B - Synthetic method of somalupeptide - Google Patents
Synthetic method of somalupeptide Download PDFInfo
- Publication number
- CN113637064B CN113637064B CN202010393322.2A CN202010393322A CN113637064B CN 113637064 B CN113637064 B CN 113637064B CN 202010393322 A CN202010393322 A CN 202010393322A CN 113637064 B CN113637064 B CN 113637064B
- Authority
- CN
- China
- Prior art keywords
- fmoc
- resin
- added
- dmf
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010189 synthetic method Methods 0.000 title description 2
- 239000011347 resin Substances 0.000 claims abstract description 142
- 229920005989 resin Polymers 0.000 claims abstract description 142
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000012634 fragment Substances 0.000 claims abstract description 23
- 238000000746 purification Methods 0.000 claims abstract description 9
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 7
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 18
- 238000010168 coupling process Methods 0.000 abstract description 15
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 239000012043 crude product Substances 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 9
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 abstract description 6
- 230000008878 coupling Effects 0.000 abstract description 6
- 238000005859 coupling reaction Methods 0.000 abstract description 6
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract description 5
- 230000006340 racemization Effects 0.000 abstract description 5
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000001308 synthesis method Methods 0.000 abstract description 3
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 abstract description 2
- 238000005336 cracking Methods 0.000 abstract description 2
- 239000007858 starting material Substances 0.000 abstract description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 263
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 132
- 238000002156 mixing Methods 0.000 description 79
- 238000005406 washing Methods 0.000 description 75
- 239000000203 mixture Substances 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 64
- 239000000243 solution Substances 0.000 description 59
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 239000000706 filtrate Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 24
- 238000005303 weighing Methods 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 20
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 16
- 238000003756 stirring Methods 0.000 description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000001291 vacuum drying Methods 0.000 description 13
- -1 fmoc-Gly-OH Chemical class 0.000 description 12
- 239000006166 lysate Substances 0.000 description 12
- 239000011259 mixed solution Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 9
- 238000000967 suction filtration Methods 0.000 description 7
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical group CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 6
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 6
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- DBTMQODRSDEGRZ-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(2-oxoethyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCC=O)C3=CC=CC=C3C2=C1 DBTMQODRSDEGRZ-UHFFFAOYSA-N 0.000 description 5
- 239000003875 Wang resin Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 3
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 3
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 3
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 3
- HOZZVEPRYYCBTO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-2-methylpropanoic acid Chemical compound C1=CC=C2C(COC(=O)NC(C)(C)C(O)=O)C3=CC=CC=C3C2=C1 HOZZVEPRYYCBTO-UHFFFAOYSA-N 0.000 description 3
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 2
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 2
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 2
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 2
- XQPYRJIMPDBGRW-UHFFFAOYSA-N 2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCC(=O)O)C3=CC=CC=C3C2=C1 XQPYRJIMPDBGRW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 2
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 108010004034 stable plasma protein solution Proteins 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 1
- ZRHPMMZWDWMKPD-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]imidazol-4-yl]propanoic acid Chemical compound CC(C)(C)OC(=O)N1C=NC(C[C@H](NC(=O)OCC2C3=CC=CC=C3C3=CC=CC=C32)C(O)=O)=C1 ZRHPMMZWDWMKPD-QFIPXVFZSA-N 0.000 description 1
- HJJURMMMGPQIQP-DEOSSOPVSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-phenylmethoxypentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)OCC1=CC=CC=C1 HJJURMMMGPQIQP-DEOSSOPVSA-N 0.000 description 1
- OYXZPXVCRAAKCM-SANMLTNESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OYXZPXVCRAAKCM-SANMLTNESA-N 0.000 description 1
- UCDMMWCWPVCHLL-OSPHWJPCSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylmethoxybutanoic acid Chemical compound O([C@H](C)[C@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(O)=O)CC1=CC=CC=C1 UCDMMWCWPVCHLL-OSPHWJPCSA-N 0.000 description 1
- WDUQJXKBWRNMKI-UHFFFAOYSA-N 18-[(2-methylpropan-2-yl)oxy]-18-oxooctadecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCC(O)=O WDUQJXKBWRNMKI-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- MVMZFAIUUXYFGY-FYZYNONXSA-N [(5s)-5-carboxy-5-(9h-fluoren-9-ylmethoxycarbonylamino)pentyl]azanium;chloride Chemical compound Cl.C1=CC=C2C(COC(=O)N[C@@H](CCCCN)C(O)=O)C3=CC=CC=C3C2=C1 MVMZFAIUUXYFGY-FYZYNONXSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
The invention discloses a synthesis method of a somalupeptide, which comprises the following steps: the S1-S3 fragment and the S4-S6 fragment which are fully protected by the somalupeptide are respectively synthesized and used for synthesizing the somalupeptide resin, and the somalupeptide is obtained through cracking and purifying. The method also comprises the step of synthesizing the lysine with the side chain group at the 20 th position of the sorulon, and the segment is favorable for completing the coupling of the sorulon main chain, so that the purity and the yield of a sorulon crude product are greatly improved, and the synthesis cost is reduced. In the method, the fully protected S1-S3 fragment and the fully protected S4-S6 fragment of the somalundum are prepared, and are used as key starting materials for solid-phase synthesis of the somalundum, so that the production of D-His, D-Glu, D-Thr, D-Phe racemization impurities and +Gly impurities is greatly reduced, the difficulty of crude purification is obviously reduced, the purity and yield of the somalundum are greatly improved, the synthesis cost is reduced, and the industrial mass production is facilitated.
Description
Technical Field
The invention relates to the field of polypeptide synthesis, in particular to a method for preparing a somalupeptide.
Technical Field
Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by human intestinal L cells, and has effects of promoting insulin secretion, inhibiting glucagon secretion, and lowering blood sugar concentration, and can be used for treating type II diabetes. However, natural GLP-1 is unstable in vivo and is susceptible to rapid degradation by dipeptidyl peptidase-IV (DPP-IV).
Somamunotide, named Semaglutide, is a novel long-acting glucagon-like peptide-1 (GLP-1) analog developed and produced by Daneno and Norde corporation for the treatment of type II diabetes. The somalunin has the effects of reducing blood sugar, losing weight and protecting cardiovascular system, and is approved by FDA in 12 months of 2017. After the Lys side chain of the somalundum is modified by PEG, glu and octadecadicarboxylic acid, the hydrophilicity is greatly improved, and the binding force with albumin is enhanced; meanwhile, after Ala at the 2 nd position of the N end is mutated into Aib, the inactivation caused by DPP-IV enzymolysis is effectively avoided, the half life reaches 40h, and patients only need to inject once a week. The CAS number of the somalundum is 910463-68-2, the molecular formula is C187H291N45O59, the molecular weight is 4113.64g/mol, and the peptide sequence is:
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-Octadecanedioic)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH。
the methods for preparing somalundin reported so far are roughly divided into two categories: one is to directly access Lys containing side chain as fragment into the main chain of the somalupeptide to complete synthesis, patent CN104356224A discloses a method of using liquid phase method to synthesize epsilon-NH of Lys 2 A method for preparing the somalundin by grafting a side chain and then gradually condensing amino acid on resin. The other is to finish the coupling of the main chain and the side chain of the cable-marlutide one by one, and patent CN 201511027176 discloses that the cable-marlutide linear peptide is synthesized gradually in a solid phase, a side chain modification group is synthesized, a protecting group of Lys is removed, the side chain modification group is coupled, and finally the polypeptide product is obtained by cleavage. Because the sequence of the somalupeptide is longer and has more hydrophobic amino acids, the somalupeptide is easy to form folding when synthesized by adopting an amino acid gradual condensation method, the shrinkage of resin is serious, the reaction time is prolonged, and more impurities with very similar properties to products, such as [ D-His ] are generated in the crude peptide]Is a racemic impurity of (2)
H-D-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-Octadecane-dioic)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH;+Gly
Impurity(s)
H-His-Aib-Glu-Gly-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-Octadecanedioic)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH;D-Phe
Impurity(s)
H-His-Aib-Glu-Gly-Thr-D-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Octadecanedioicacidmono-tert-butyl
ester-gamma-Glu-PEG-PEG) -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH; the [ D-His ] racemization impurity is similar to the physicochemical property of the target peptide of the somalundum, so that the separation and purification difficulty of the somalundum product is greatly increased, and the product yield is greatly reduced. Therefore, there is an urgent need for a method for synthesizing somalundin with high purity and yield and low synthesis cost.
Disclosure of Invention
The invention provides a synthesis method of the simaroubm peptide with high yield and high purity, which aims to solve the problems of more impurities, low purity and yield, high cost, complex operation steps, unfavorable industrial production and the like in the existing synthesis process. The strategy of adding tripeptide and tripeptide fragments is adopted to reduce the generation of D-His racemization impurity, +Gly impurity, D-Thr and D-Phe impurity, and has considerable economic and applicable value and wide application prospect.
In order to achieve the aim of the invention, the invention provides a synthesis method of the somalundum, which is used for respectively synthesizing the somalundum full protection S1-S3 fragment and the S4-S6 fragment, and is applied to the synthesis of the somalundum full protection peptide resin, and the somalundum is obtained through cracking and purifying.
It should be noted that in the present invention, S1 is the first amino acid at the N-terminal in the somalupeptide peptide sequence, and similarly S2, S3, S4, S5, S6, S18, S19, S20 are the 2 nd, 3 rd, 4 th, 5 th, 6 th, 18 th, 19 th, 20 th amino acids at the N-terminal, respectively, and so on.
Preferably, the fully protected S1-S3 fragment is R1-His (R2) -Aib-Glu (OR) 3 ) The full-protection S4-S6 fragment is R4-Gly-Thr (R5) -Phe-OH, wherein
R 1 Selected from the group consisting of Fmoc, dde, alloc, boc, trt, dmb, mmt, mtt,
R 2 selected from the group consisting of Fmoc, dde, alloc, boc, trt, dmb, mmt, mtt,
R 3 is selected from the group consisting of tBu and Bzl,
R 4 selected from the group consisting of Fmoc,
R 5 selected from tBu and Bzl.
More preferably, R1 is selected from: boc or Fmoc, R2 is selected from: trt or Boc, R3 is selected from tBu, R4 is selected from Fmoc, and R5 is selected from tBu.
In some embodiments R 1 Is Boc, R 2 Is Trt, R 3 Is tBu, R 4 Fmoc, R 5 Is tBu, namely: the S1-S3 fragment is Boc-His (Trt) -Aib-Glu (OtBu) -OH, and the S4-S6 fragment is Fmoc-Gly-Thr (tBu) -Phe-OH. The adoption of the full-protection S1-S3 fragment Boc-His (Trt) -Aib-Glu (OtBu) -OH can effectively reduce the generation of D-His racemization impurities; the adoption of full protection, the S4-S6 fragment Fmoc-Gly-Thr (tBu) -Phe-OH can effectively reduce the generation of +Gly impurity, D-Thr and D-Phe impurity, and the use of the two fragments can obviously improve the yield and purity of the crude peptide of the somalundin.
The applicant has unexpectedly found that in the preparation of the somalundum peptide, the monomer Fmoc-Lys (AEEa-AEEa-gamma-Glu (OtBu) -Octadecanantioic) -OH is adopted at the 20 th position, so that a peptide intermediate can be easily inserted into SPPS, an amino terminal amino acid can be more easily reacted with the SPPS, mismatched peptide impurities (such as amino acid missing peptide and amino acid superfluous peptide) and racemic peptide impurities can be obviously inhibited/reduced, and the yield and purity of the crude somalundum peptide are obviously improved.
In some embodiments, S20 is: fmoc-Lys (AEEA-AEEA-gamma-Glu (OtBu) -Octadecananioic) -OH, S1-S3 fragments are: the Boc-His (Trt) -Aib-Glu (OtBu) -OH, S4-S6 fragment is: fmoc-Gly-Thr (tBu) -Phe-OH.
According to the invention, the solid-phase synthesis method combining the fragment and the stepwise synthesis is adopted to prepare the S1-S3 fragment and the S4-S6 fragment of the somalupeptide, and the fragments are used as key starting materials for the solid-phase synthesis of the somalupeptide, so that the generation of D-His, D-Glu, D-Thr, D-Phe racemization impurities and +Gly impurities is greatly reduced, the difficulty of crude product purification is obviously reduced, the purity and yield of the somalupeptide are greatly improved, the synthesis cost is reduced, and the industrial mass production is facilitated.
Drawings
FIG. 1 is an HPLC chromatogram of crude peptide of somalupeptide prepared in example 8
FIG. 2 is an HPLC chromatogram of the somalupeptide refined peptide prepared in example 11
Detailed Description
The foregoing of the invention will be described in further detail with reference to specific embodiments. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
The meanings of the abbreviations used in the present invention are listed in the following table:
EXAMPLE 1 preparation of Boc-His (Trt) -Aib-Glu (OtBu) -OH
A. 150g of 2-CTC resin with substitution degree of 1.06mmol/g is added into a reaction kettle, 500ml of dichloromethane is added, after mixing for 2min, dichloromethane is filtered off, 500ml of dichloromethane is added again, after mixing for 40min, dichloromethane is filtered off, finally 500ml of dichloromethane is added again, after mixing for 2min, dichloromethane is filtered off, and the resin is ready for use.
B. 135.30g of Fmoc-Glu (OtBu) -OH was weighed into a beaker, 500ml of DMF and 78.83ml of DIEA were added, the solution was stirred at 0-10℃for 5min and then poured into the CTC resin obtained in step A, and the mixture was reacted for 4h at 20-25 ℃. After the reaction is finished, DMF is filtered off. A mixed solution of 25ml of methanol and 250ml of DMF, a mixed solution of 50ml of DIEA and 250ml of DMF was added to the resin, and the mixing reaction was continued for 1h. After the reaction is finished, carrying out suction filtration, and washing the resin with DMF for 5 times, wherein 500ml of the resin is used each time; after washing, methanol is used for washing twice, and 500ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 500ml; finally, the resin was washed 3 times with 500ml portions of methanol until the resin was sufficiently dispersed.
C. And (3) drying the resin obtained in the step (B) in a vacuum drying oven at 20-30 ℃ for 4 hours until the weight is constant (twice weighing is carried out continuously, and the error is lower than 1%). After drying, 211.89g of Fmoc-Glu (OtBu) -CTC resin was obtained, and the degree of substitution was detected to be 0.75mmol/g.
D. The Fmoc-Glu (OtBu) -CTC resin obtained in step C was poured into a reaction vessel, swollen with 500ml DCM, mixed for 15min and then pumped down. 500ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF500ml was added and after mixing for 5min, the mixture was drained. 500ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF500ml was added and after mixing for 5min, the mixture was drained. Repeated DMF washing 5 times, 500ml each time, mixing 5min each time, and after washing 4 times, the filtrate was checked with PH test paper, which showed that PH was acceptable at 6.5-7.0.
E. 103.39g Fmoc-Aib-OH, 48.16g DIC and 51.57g HOBT were weighed in sequence in a clean 1L beaker, 500ml of DMF/DCM solution in a volume ratio of 1:1 was added, and the mixture was placed in ice water and stirred with a mechanical stirrer at 0-10℃for dissolution, and after the temperature was constant, the temperature was maintained and stirring was continued for 5min. Slowly adding the activating solution into a reaction kettle, and mixing and reacting for 2 hours at 20-25 ℃. After the reaction, the mixture was drained, 500ml of DMF was added thereto, and after 5 minutes of mixing, the mixture was drained. The DMF washes were repeated 5 times, 500ml each time, and 5min each time of mixing. Finally, detecting the obtained product as negative by ninhydrin to obtain Fmoc-Aib-Glu (OtBu) -CTC resin.
F. The amino acid Boc-His (Trt) -OH was coupled as described above for the deprotection method of step D and the coupling method of step E. Finally, washing with dichloromethane for 5 times, each time 500ml; after washing, methanol is used for washing twice, and 500ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 500ml; finally, the resin was washed 3 times with 500ml portions of methanol until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 245.31g of a fully protected Boc-His (Trt) -Aib-Glu (OtBu) -CTC resin was obtained.
G. The lysate ratio is TFE: DCM=1:4 (volume ratio), 20g of the full-protection peptide resin of the CTC resin obtained in the step F is added into 200mL of lysate at 15 ℃, the temperature is raised to 30 ℃, the reaction is continued for 3 hours by stirring, then the filtered resin is filtered by a sand core funnel, the filtered resin is washed by 100mL of DCM, the filtrate is combined after repeated operation for two times, the filtrate is concentrated under reduced pressure until the volume of the filtrate is 30% of the original volume, then the concentrated solution is slowly added into precooled 1L of isobutyl ether, the mixture is centrifuged for 5 times after sedimentation, 200mL of isobutyl ether is used each time, white solid powder is obtained, the mixture is dried by nitrogen gas firstly, then dried by a vacuum drying box for 10 hours, and 7.65g of full-protection Boc-His (Trt) -Aib-Glu (OtBu) -OH crude product is obtained after weighing.
EXAMPLE 2 preparation of Fmoc-His (Boc) -Aib-Glu (OBzl) -OH
A. 100g of 2-CTC resin with substitution degree of 1.12mmol/g is added into a reaction kettle, 300ml of dichloromethane is added, after mixing for 2min, dichloromethane is filtered off, 300ml of dichloromethane is added again, after mixing for 40min, dichloromethane is filtered off, finally 300ml of dichloromethane is added again, after mixing for 2min, dichloromethane is filtered off, and the resin is ready for use.
B. 102.93g of Fmoc-Glu (OBzl) -OH was weighed into a beaker, 300ml of DMF and 55.53ml of DIEA were added, the solution was stirred at 0-10℃for 5min and then poured into the CTC resin obtained in step A, and the mixture was reacted for 4h at 20-25 ℃. After the reaction is finished, DMF is filtered off. A mixed solution of 20ml of methanol and 150ml of DMF, a mixed solution of 30ml of DIEA and 150ml of DMF was added to the resin, and the mixing reaction was continued for 1h. After the reaction is finished, carrying out suction filtration, and washing the resin with DMF for 5 times, wherein 300ml of the resin is used each time; after washing, the mixture is washed twice with 300ml of methanol each time; washing with dichloromethane for 2 times, 300ml each time; finally, the resin was washed 3 times with 300ml portions of methanol until the resin was sufficiently dispersed.
C. And (3) drying the resin obtained in the step (B) in a vacuum drying oven at 20-30 ℃ for 4 hours until the weight is constant (twice weighing is carried out continuously, and the error is lower than 1%). After drying, 146.54g of Fmoc-Glu (OBzl) -CTC resin was obtained, which showed a degree of substitution of 0.76mmol/g.
D. The Fmoc-Glu (OBzl) -CTC resin obtained in step C was poured into the reaction vessel, swollen with 300ml DCM and mixed for 15min, and then pumped down. 500ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF (300 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. 300ml of 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF (300 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. Repeated DMF washing for 5 times, 300ml each time, mixing for 5min each time, and after the 4 th washing, detecting the filtrate by using PH test paper, and the result shows that the PH is 6.5-7.0.
E. 72.77g Fmoc-Aib-OH, 33.93g DIC and 36.33g HOBT were weighed in sequence in a clean 1L beaker, 300ml of DMF/DCM solution in a volume ratio of 1:1 was added, and the mixture was placed in ice water and stirred with a mechanical stirrer at 0-10℃for dissolution, and after the temperature was constant, the temperature was maintained and stirring was continued for 5min. Slowly adding the activating solution into a reaction kettle, and mixing and reacting for 2 hours at 20-25 ℃. After the reaction was completed, the mixture was drained, 300ml of DMF was added thereto, and after mixing for 5 minutes, the mixture was drained. The DMF washes were repeated 5 times, 300ml each time, and 5min each time of mixing. Finally, detecting the obtained product as negative by ninhydrin to obtain Fmoc-Aib-Glu (OBzl) -CTC resin.
F. The amino acid Fmoc-His (Boc) -OH was coupled as described above for the deprotection method of step D and the coupling method of step E. Finally, washing with dichloromethane for 5 times, 300ml each time; after washing, the mixture is washed twice with 300ml of methanol each time; washing with dichloromethane for 2 times, 300ml each time; finally, the resin was washed 3 times with 300ml portions of methanol until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 185.76g of a fully-protected Fmoc-His (Boc) -Aib-Glu (OBzl) -CTC resin was obtained.
G. The lysate ratio is TFE: DCM=1:4 (volume ratio), 30g of the full protection peptide resin of the CTC resin obtained in the step F is added into 300mL of lysate at 15 ℃, the temperature is raised to 30 ℃, the reaction is continued for 3 hours by stirring, then the filtered resin is filtered by a sand core funnel, the filtered resin is washed by 150mL of DCM, the filtrate is combined after repeated operation for two times, the filtrate is concentrated under reduced pressure until the volume of the filtrate is 30% of the original volume, then the concentrated solution is slowly added into precooled 1L of isobutyl ether, the mixture is centrifuged for 5 times after sedimentation, 200mL of isobutyl ether is used each time, white solid powder is obtained, the mixture is dried by nitrogen gas firstly, then dried by a vacuum drying box for 10 hours, and 12.95g of full protection Fmoc-His (Boc) -Aib-Glu (OBzl) -OH crude product is obtained after weighing.
EXAMPLE 3 preparation of Fmoc-His (Trt) -Aib-Glu (OtBu) -OH
A. 120g of 2-CTC resin with substitution degree of 1.06mmol/g is added into a reaction kettle, 400ml of dichloromethane is added, after mixing for 2min, the dichloromethane is filtered off, 400ml of dichloromethane is added again, after mixing for 40min, the dichloromethane is filtered off, finally 400ml of dichloromethane is added again, after mixing for 2min, the dichloromethane is filtered off, and the resin is ready for use.
B. 108.24g of Fmoc-Glu (OtBu) -OH was weighed into a beaker, 400ml of DMF and 63.06ml of DIEA were added, the solution was stirred at 0-10℃for 5min and then poured into the CTC resin obtained in step A, and the mixture was reacted for 4h at 20-25 ℃. After the reaction is finished, DMF is filtered off. A mixed solution of 20ml of methanol and 200ml of DMF, a mixed solution of 30ml of DIEA and 200ml of DMF was added to the resin, and the mixing reaction was continued for 1h. After the reaction is finished, carrying out suction filtration, and washing the resin with DMF for 5 times, wherein 400ml of the resin is used each time; after washing, methanol is used for washing twice, 400ml each time; washing with dichloromethane for 2 times, 400ml each time; finally, the resin was washed 3 times with 400ml portions of methanol until the resin was sufficiently dispersed.
C. And (3) drying the resin obtained in the step (B) in a vacuum drying oven at 20-30 ℃ for 4 hours until the weight is constant (twice weighing is carried out continuously, and the error is lower than 1%). After drying, 175.21g of Fmoc-Glu (OtBu) -CTC resin was obtained, and the degree of substitution was detected to be 0.73mmol/g.
D. The Fmoc-Glu (OtBu) -CTC resin obtained in step C was poured into a reaction vessel, swollen with 400ml DCM, mixed for 15min and then pumped down. 500ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF400ml was added and after mixing for 5min, the mixture was drained. 400ml of 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF400ml was added and after mixing for 5min, the mixture was drained. Repeated DMF washing for 5 times, 400ml each time, mixing for 5min each time, and after the 4 th washing, detecting the filtrate by using PH test paper, and the result shows that the PH is 6.5-7.0.
E. 82.71g Fmoc-Aib-OH, 38.53g DIC and 41.26g HOBT were weighed in sequence in a clean 1L beaker, 400ml of DMF/DCM solution in a volume ratio of 1:1 was added, and the mixture was placed in ice water and stirred with a mechanical stirrer at 0-10℃for dissolution, and after the temperature was constant, the temperature was maintained and stirring was continued for 5min. Slowly adding the activating solution into a reaction kettle, and mixing and reacting for 2 hours at 20-25 ℃. After the reaction was completed, the mixture was drained, and after adding 400ml of DMF and mixing for 5 minutes, the mixture was drained. The DMF washes were repeated 5 times, 400ml each time, and 5min each time of mixing. Finally, detecting the obtained product as negative by ninhydrin to obtain Fmoc-Aib-Glu (OtBu) -CTC resin.
F. The amino acid Fmoc-His (Trt) -OH was coupled as described above for the deprotection method of step D and the coupling method of step E. Finally, washing with dichloromethane for 5 times, each time 400ml; after washing, methanol is used for washing twice, 400ml each time; washing with dichloromethane for 2 times, 400ml each time; finally, the resin was washed 3 times with 400ml portions of methanol until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 208.64g of a fully-protected Fmoc-His (Trt) -Aib-Glu (OtBu) -CTC resin was obtained.
G. The lysate ratio is TFE: DCM=1:4 (volume ratio), 20g of the full-protection peptide resin of the CTC resin obtained in the step F is added into 200mL of lysate at 15 ℃, the temperature is raised to 30 ℃, the reaction is continued for 3 hours by stirring, then the filtered resin is filtered by a sand core funnel, the filtered resin is washed by 100mL of DCM, the filtrate is combined after repeated operation for two times, the filtrate is concentrated under reduced pressure until the volume of the filtrate is 30% of the original volume, then the concentrated solution is slowly added into precooled 1L of isobutyl ether, the mixture is centrifuged for 5 times after sedimentation, 200mL of isobutyl ether is used each time, white solid powder is obtained, the mixture is dried by nitrogen gas firstly, then dried by a vacuum drying box for 10 hours, and 8.25g of the full-protection Fmoc-His (Trt) -Aib-Glu (OtBu) -OH crude product is obtained after weighing.
EXAMPLE 4 preparation of Fmoc-Gly-Thr (tBu) -Phe-OH
A. 150g of 2-CTC resin with substitution degree of 1.10mmol/g is added into a reaction kettle, 500ml of dichloromethane is added, after mixing for 2min, dichloromethane is filtered off, 500ml of dichloromethane is added again, after mixing for 40min, dichloromethane is filtered off, finally 500ml of dichloromethane is added again, after mixing for 2min, dichloromethane is filtered off, and the resin is ready for use.
B. 127.85g of Fmoc-Phe-OH was weighed into a beaker, 500ml of DMF and 81.81ml of DIEA were added, the solution was stirred and activated at 0-10℃for 5min, then poured into the CTC resin obtained in step A, and mixed and reacted at 20-25℃for 4h. After the reaction is finished, DMF is filtered off. A mixed solution of 25ml of methanol and 250ml of DMF, a mixed solution of 40ml of DIEA and 250ml of DMF was added to the resin, and the mixing reaction was continued for 1h. After the reaction is finished, carrying out suction filtration, and washing the resin with DMF for 5 times, wherein 500ml of the resin is used each time; after washing, methanol is used for washing twice, and 500ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 500ml; finally, the resin was washed 3 times with 500ml portions of methanol until the resin was sufficiently dispersed.
C. And (3) drying the resin obtained in the step (B) in a vacuum drying oven at 20-30 ℃ for 4 hours until the weight is constant (twice weighing is carried out continuously, and the error is lower than 1%). After drying, 205.46g of Fmoc-Phe-CTC resin were obtained, the degree of substitution detected being 0.80mmol/g.
D. The Fmoc-Phe-CTC resin obtained in step C was poured into the reaction vessel, swollen with 500ml DCM and mixed for 15min, and then pumped down. 500ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF500ml was added and after mixing for 5min, the mixture was drained. 500ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF500ml was added and after mixing for 5min, the mixture was drained. Repeated DMF washing 5 times, 500ml each time, mixing 5min each time, and after washing 4 times, the filtrate was checked with PH test paper, which showed that PH was acceptable at 6.5-7.0.
E. 131.16g Fmoc-Thr (tBu) -OH, 49.98g DIC and 53.51g HOBT were weighed in sequence in a clean 1L beaker, 500ml of DMF/DCM solution was added in a volume ratio of 1:1, and placed in ice water and stirred with a mechanical stirrer at 0-10℃for dissolution, after the temperature was constant, the temperature was maintained and stirring was continued for 5min. Slowly adding the activating solution into a reaction kettle, and mixing and reacting for 2 hours at 20-25 ℃. After the reaction, the mixture was drained, 500ml of DMF was added thereto, and after 5 minutes of mixing, the mixture was drained. The DMF washes were repeated 5 times, 500ml each time, and 5min each time of mixing. Finally, detecting the obtained product as negative by ninhydrin to obtain Fmoc-Thr (tBu) -Phe-CTC resin.
F. The amino acid Fmoc-Gly-OH was coupled as described above for the deprotection method of step D and the coupling method of step E. Finally, washing with dichloromethane for 5 times, each time 500ml; after washing, methanol is used for washing twice, and 500ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 500ml; finally, the resin was washed 3 times with 500ml portions of methanol until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 236.15g of a fully protected Fmoc-Gly-Thr (tBu) -Phe-CTC resin was obtained.
G. The mixture ratio of the lysate is TFE (TFE) =1:4 (volume ratio), 20g of the full-protection peptide resin of the CTC resin obtained in the step F is added into 200mL of lysate at 15 ℃, the temperature is raised to 30 ℃, the reaction is continued for 3 hours by stirring, then the filtered resin is filtered by a sand core funnel, the filtered resin is washed by 100mL of DCM, the filtrate is combined after repeated operation for two times, the filtrate is concentrated under reduced pressure until the volume of the filtrate is 30% of the original volume, then the concentrated solution is slowly added into precooled 1L of isobutyl ether, the mixture is centrifuged for 5 times after sedimentation, 200mL of isobutyl ether is used each time, white solid powder is obtained, the mixture is dried by nitrogen, then dried by a vacuum drying box for 10 hours, and 7.39g of the full-protection Fmoc-Gly-Thr (tBu) -Phe-OH crude product is obtained after weighing.
EXAMPLE 5 Fmoc-Gly-Thr (Bzl) -Phe-OH preparation
A. 100g of 2-CTC resin with substitution degree of 1.10mmol/g is added into a reaction kettle, 300ml of dichloromethane is added, after mixing for 2min, dichloromethane is filtered off, 300ml of dichloromethane is added again, after mixing for 40min, dichloromethane is filtered off, finally 300ml of dichloromethane is added again, after mixing for 2min, dichloromethane is filtered off, and the resin is ready for use.
B. 85.23g Fmoc-Phe-OH was weighed into a beaker, 300ml DMF and 54.54ml DIEA were added, the solution was stirred and activated at 0-10℃for 5min, then poured into the CTC resin obtained in step A, and mixed and reacted at 20-25℃for 4h. After the reaction is finished, DMF is filtered off. A mixed solution of 20ml of methanol and 150ml of DMF, a mixed solution of 25ml of DIEA and 150ml of DMF was added to the resin, and the mixing reaction was continued for 1h. After the reaction is finished, carrying out suction filtration, and washing the resin with DMF for 5 times, wherein 300ml of the resin is used each time; after washing, the mixture is washed twice with 300ml of methanol each time; washing with dichloromethane for 2 times, 300ml each time; finally, the resin was washed 3 times with 300ml portions of methanol until the resin was sufficiently dispersed.
C. And (3) drying the resin obtained in the step (B) in a vacuum drying oven at 20-30 ℃ for 4 hours until the weight is constant (twice weighing is carried out continuously, and the error is lower than 1%). After drying, 136.84g of Fmoc-Phe-CTC resin was obtained, the degree of substitution detected being 0.80mmol/g.
D. The Fmoc-Phe-CTC resin obtained in step C was poured into the reaction vessel, swollen with 300ml DCM and mixed for 15min, and then pumped down. 300ml of 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF (300 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. 300ml of 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF (300 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. Repeated DMF washing for 5 times, 300ml each time, mixing for 5min each time, and after the 4 th washing, detecting the filtrate by using PH test paper, and the result shows that the PH is 6.5-7.0.
E. 87.44g Fmoc-Thr (Bzl) -OH, 33.32g DIC and 35.67g HOBT were weighed in sequence in a clean 1L beaker, 300ml of DMF/DCM solution in a volume ratio of 1:1 was added, and the mixture was placed in ice water and stirred with a mechanical stirrer at 0-10℃for dissolution, and after the temperature was constant, the temperature was maintained and stirring was continued for 5min. Slowly adding the activating solution into a reaction kettle, and mixing and reacting for 2 hours at 20-25 ℃. After the reaction was completed, the mixture was drained, 300ml of DMF was added thereto, and after mixing for 5 minutes, the mixture was drained. The DMF washes were repeated 5 times, 300ml each time, and 5min each time of mixing. Finally, detecting the obtained product as negative by ninhydrin to obtain Fmoc-Thr (Bzl) -Phe-CTC resin.
F. The amino acid Fmoc-Gly-OH was coupled as described above for the deprotection method of step D and the coupling method of step E. Finally, washing with dichloromethane for 5 times, 300ml each time; after washing, the mixture is washed twice with 300ml of methanol each time; washing with dichloromethane for 2 times, 300ml each time; finally, the resin was washed 3 times with 300ml portions of methanol until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 160.86g of a fully protected Fmoc-Gly-Thr (Bzl) -Phe-CTC resin was obtained.
G. The mixture ratio of the lysate is TFE (TFE) =1:4 (volume ratio), 20g of the full-protection peptide resin of the CTC resin obtained in the step F is added into 200mL of lysate at 15 ℃, the temperature is raised to 30 ℃, the reaction is continued for 3 hours by stirring, then the filtered resin is filtered by a sand core funnel, the filtered resin is washed by 100mL of DCM, the filtrate is combined after repeated operation for two times, the filtrate is concentrated under reduced pressure until the volume of the filtrate is 30% of the original volume, then the concentrated solution is slowly added into precooled 1L of isobutyl ether, the mixture is centrifuged for 5 times after sedimentation, 200mL of isobutyl ether is used each time, white solid powder is obtained, the mixture is dried by nitrogen firstly, then dried by a vacuum drying box for 10 hours, and 7.84g of full-protection Fmoc-Gly-Thr (Bzl) -Phe-OH crude product is obtained after weighing.
EXAMPLE 6 preparation of Fmoc-Lys (AEEA-AEEA-gamma-Glu (OtBu) -Octadecananic) -OH
A. 150g of 2-CTC resin with substitution degree of 1.05mmol/g is added into a reaction kettle, 500ml of dichloromethane is added, after mixing for 2min, dichloromethane is filtered off, 500ml of dichloromethane is added again, after mixing for 40min, dichloromethane is filtered off, finally 500ml of dichloromethane is added again, after mixing for 2min, dichloromethane is filtered off, and the resin is ready for use.
B. 121.44g of Fmoc-AEEA-OH was weighed into a beaker, 500ml of DMF and 76.18ml of DIEA were added, the solution was stirred at 0-10℃for 5min, and then poured into the CTC resin obtained in step A, and mixed and reacted at 20-25℃for 4h. After the reaction is finished, DMF is filtered off. A mixed solution of 25ml of methanol and 250ml of DMF, a mixed solution of 40ml of DIEA and 250ml of DMF was added to the resin, and the mixing reaction was continued for 1h. After the reaction is finished, carrying out suction filtration, and washing the resin with DMF for 5 times, wherein 500ml of the resin is used each time; after washing, methanol is used for washing twice, and 500ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 500ml; finally, the resin was washed 3 times with 500ml portions of methanol until the resin was sufficiently dispersed.
C. And (3) drying the resin obtained in the step (B) in a vacuum drying oven at 20-30 ℃ for 4 hours until the weight is constant (twice weighing is carried out continuously, and the error is lower than 1%). After drying, 140.20 mmole Fmoc-AEEA-CTC resin was obtained, and the degree of substitution was detected to be 0.73 mmole/g.
D. The Fmoc-AEEA-CTC resin obtained in step C was poured into the reactor, swelled and mixed with 500ml DCM for 15min, and then pumped down. 500ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF500ml was added and after mixing for 5min, the mixture was drained. 500ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF500ml was added and after mixing for 5min, the mixture was drained. Repeated DMF washing 5 times, 500ml each time, mixing 5min each time, and after washing 4 times, the filtrate was checked with PH test paper, which showed that PH was acceptable at 6.5-7.0.
E. 108.07g Fmoc-AEEA-OH, 35.42g DIC and 39.59g HOBT were weighed in sequence in a clean 1L beaker, 500ml of DMF/DCM solution in a volume ratio of 1:1 was added, the mixture was placed in ice water and stirred with a mechanical stirrer at 0-10℃for dissolution, and after the temperature was constant, the temperature was maintained and stirring was continued for 5min. Slowly adding the activating solution into a reaction kettle, and mixing and reacting for 2 hours at 20-25 ℃. After the reaction, the mixture was drained, 500ml of DMF was added thereto, and after 5 minutes of mixing, the mixture was drained. The DMF washes were repeated 5 times, 500ml each time, and 5min each time of mixing. Finally, detecting the obtained product as negative by ninhydrin to obtain Fmoc-AEEA-AEEA-CTC resin.
F. According to the deprotection method of the step D and the coupling method of the step E, the amino acid Fmoc-Glu (OH) -OtBu and the octadecanedioic acid mono-tert-butyl ester are respectively coupled in sequence. Finally, washing with dichloromethane for 5 times, each time 500ml; after washing, methanol is used for washing twice, and 500ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 500ml; finally, the alcohol was used 3 times, 500ml each, until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 255.40g of Octadecanadioic-gamma-Glu (OtBu) -AEEA-AEEA-CTC resin was obtained.
G. The lysate ratio is TFE: DCM=1:4 (volume ratio), 30g of the full-protection peptide resin of the CTC resin obtained in the step F is added into 300mL of lysate at 15 ℃, the temperature is raised to 30 ℃, the reaction is continued for 3 hours by stirring, then the filtered resin is filtered by a sand core funnel, the filtered resin is washed by 100mL of DCM, the filtrate is combined after repeated operation for two times, the filtrate is concentrated under reduced pressure until the volume of the filtrate is 30% of the original volume, then the concentrated solution is slowly added into pre-cooled 2L of isobutyl ether, the mixture is centrifuged for 5 times after sedimentation, each time 300mL of isobutyl ether is used, white solid powder is obtained, the mixture is dried by nitrogen, then dried by a vacuum drying box for 10 hours, and 11.65g of the crude product of Octadecananic-gamma-Glu (OtBu) -EA-AEEA-OH is obtained after weighing.
H. 5G of crude Octadecanadic-gamma-Glu (OtBu) -AEEA-AeEA-OH obtained in step G was dissolved in 10mL of CM, and 2.2G of pentafluorophenol was added. 2.4g of DCC was weighed and dissolved in 10mM DCM, the DCC solution was slowly added dropwise to the reaction solution, the reaction was stirred for 1.0h, and after completion of the TLC detection, the reaction was filtered. The filtrate was washed once with saturated brine, once with water, and the DCM solution was dried over anhydrous sodium sulfate, concentrated to dryness, and dissolved in an appropriate amount of acetonitrile. 6.08g Fmoc-Lys-OH.HCl was weighed out and dissolved in acetonitrile/water (acetonitrile/water=1/2), 7.5ml of LDIEA was added and stirred for 15 minutes. The above reaction solution was slowly added dropwise to the Fmoc-Lys-OH solution and the reaction was stirred for 1.5h. Dilute hydrochloric acid was added to adjust the pH to about 6, and a small amount of DCM was added for extraction. Fmoc-Lys (AEEA-AEEA-. Gamma. -Glu (OtBu) -Octadecananic) -OH2.85g was obtained by purification.
EXAMPLE 7 preparation of Fmoc-Gly-Wang resin with substitution of 0.30mmol/g
A. 10g of Wang resin with a substitution degree of 0.90mmol/g was added to the reaction vessel, 100ml of dichloromethane was added, after mixing for 2min, dichloromethane was filtered off, 100ml of dichloromethane was added again, after mixing for 40min, dichloromethane was filtered off, finally 100ml of dichloromethane was added again, after mixing for 2min, dichloromethane was filtered off and the resin was ready for use.
B. 5.35g Fmoc-Gly-OH and 2.92g HOBT were weighed into a beaker, 100ml DMF and 4.46ml DIEA were added, the solution was stirred at 0-10℃for 5min, then poured into the Wang resin obtained in step A, 0.16g DMAP was added, and the mixture was mixed at 20-25℃for 4h. After the reaction was completed, 8.5ml of acetic anhydride was added thereto, and mixing was continued for 1 hour. After the reaction is finished, carrying out suction filtration, and washing the resin with DMF for 5 times, wherein 100ml of the resin is used each time; after washing, methanol is used for washing twice, and 100ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 100ml; finally, the resin was washed 3 times with 100ml portions of methanol until the resin was sufficiently dispersed.
C. And (3) drying the resin obtained in the step (B) in a vacuum drying oven at 20-30 ℃ for 4 hours until the weight is constant (twice weighing is carried out continuously, and the error is lower than 1%). After drying, 12.87g of Fmoc-Gly-Wang resin was obtained, and the substitution degree by ultraviolet detection was 0.30mmol/g.
EXAMPLE 8 preparation of crude Sodamantane peptide 1
A. 10g of Fmoc-Gly-Wang resin obtained in example 7 was poured into a reaction kettle, swollen with 100ml of DCM and mixed for 15min, and then pumped down. 100ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF (100 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. 100ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF (100 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. Washing with DMF was repeated 8 times, 100ml each time, mixing 5min each time, and after the seventh washing, the filtrate was checked with pH paper, which showed that the pH was acceptable at 6.5-7.0.
B. 3.89g of Fmoc-Arg (Pbf) -OH, 2.31g of TBTU and 0.97g of HOBT are weighed in sequence into a clean 1L beaker, 100ml of DMF/DCM solution with the volume ratio of 1:1 is added, the mixture is placed into ice water and stirred and dissolved by a mechanical stirrer at the temperature of 0-10 ℃, after the temperature is constant, 1.49ml of LDIEA is added, the temperature is continuously maintained and stirring and activation are carried out for 5min. Slowly adding the activating solution into a reaction kettle, and mixing for 2 hours at 20-25 ℃. After the reaction, the mixture was drained, 100ml of DMF was added thereto, and after 5 minutes of mixing, the mixture was drained. The DMF washes were repeated 6 times, 100ml each time, and 5min each time mixed. Finally, detecting the obtained product as negative by ninhydrin to obtain the Fmoc-Arg-Gly-Wang resin.
C. According to the deprotection method of the step A and the coupling method of the step B, the residual amino acids or peptide fragments are respectively coupled in sequence according to the sequence of main chain amino acids, namely: fmoc-Gly-OH, fmoc-Arg (Pbf) -OH, fmoc-Val-OH, fmoc-Leu-OH, fmoc-Trp (Boc) -OH, fmoc-Ala-OH, fmoc-Ile-OH, fmoc-Phe-OH, fmoc-Glu (OtBu) -OH, fmoc-Lys (AEEA-AEEA-gamma-Glu (OtBu) -Octadeceionic) -OH obtained in example 7, fmoc-Ala-OH, fmoc-Gln (Trt) -OH, fmoc-Gly-OH, fmoc-Glu (OtBu) -OH, fmoc-Leu-OH, fmoc-Tyr (tBu) -OH, fmoc-Ser (OtBu) -OH, fmoc-Asp (OtBu) -OH, fmoc-Asp-OH (Fmoc-OH) obtained in example 7, and Fmoc-Val-OH (Fmoc-OH) obtained in example 4. Thr-Boc-OH. After the coupling is completed, the reaction mixture is washed with dichloromethane for 5 times, 100ml each time; after washing, methanol is used for washing twice, and 100ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 100ml; finally, the resin was washed 3 times with 100ml of alcohol until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 26.15g of Somam Lu Taitai resin are obtained. HPLC chromatograms are shown in FIG. 1.
EXAMPLE 9 preparation of crude Sodamantane peptide 2
A. 10g of Fmoc-Gly-Wang resin with substitution of 0.30mmol/g was poured into the reaction kettle, swollen with 100ml of DCM and mixed for 15min, and then pumped down. 100ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF (100 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. 100ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF (100 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. Washing with DMF was repeated 8 times, 100ml each time, mixing 5min each time, and after the seventh washing, the filtrate was checked with pH paper, which showed that the pH was acceptable at 6.5-7.0.
B. 3.89g of Fmoc-Arg (Pbf) -OH, 2.31g of TBTU and 0.97g of HOBT are weighed in sequence into a clean 1L beaker, 100ml of DMF/DCM solution with the volume ratio of 1:1 is added, the mixture is placed into ice water and stirred and dissolved by a mechanical stirrer at the temperature of 0-10 ℃, after the temperature is constant, 1.49ml of LDIEA is added, the temperature is continuously maintained and stirring and activation are carried out for 5min. Slowly adding the activating solution into a reaction kettle, and mixing for 2 hours at 20-25 ℃. After the reaction, the mixture was drained, 100ml of DMF was added thereto, and after 5 minutes of mixing, the mixture was drained. The DMF washes were repeated 6 times, 100ml each time, and 5min each time mixed. Finally, detecting the obtained product as negative by ninhydrin to obtain the Fmoc-Arg-Gly-Wang resin.
C. According to the deprotection method of the step A and the coupling method of the step B, the residual amino acids or peptide fragments are respectively coupled in sequence according to the sequence of main chain amino acids, namely: fmoc-Gly-OH, fmoc-Arg (Pbf) -OH, fmoc-Val-OH, fmoc-Leu-OH, fmoc-Trp (Boc) -OH, fmoc-Ala-OH, fmoc-Ile-OH, fmoc-Phe-OH, fmoc-Glu (OtBu) -OH, fmoc-Lys (AEEA-AEEA-gamma-Glu (OtBu) -Octadeceionic) -OH obtained in example 7, fmoc-Ala-OH, fmoc-Gln (Trt) -OH, fmoc-Gly-OH, fmoc-Glu (OtBu) -OH, fmoc-Leu-OH, fmoc-Tyr (tBu) -OH, fmoc-Ser (OtBu) -OH, fmoc-Asp (OtBu) -OH, fmoc-Asp-OH (Fmoc-OH) obtained in example 7, and Fmoc-Val-OH (Fmoc-OH) obtained in example 2. BtBu-OH. After the coupling is completed, the reaction mixture is washed with dichloromethane for 5 times, 100ml each time; after washing, methanol is used for washing twice, and 100ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 100ml; finally, the resin was washed 3 times with 100ml of alcohol until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 27.08g of Somam Lu Taitai resin are obtained. The HPLC chromatogram is similar to fig. 1.
EXAMPLE 10 preparation of crude Sodamantane peptide 3
A. 10g of Fmoc-Gly-Wang resin obtained in example 7 was poured into a reaction kettle, swollen with 100ml of DCM and mixed for 15min, and then pumped down. 100ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 5min, followed by draining. DMF (100 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. 100ml of a 20% piperidine/DMF solution was added and mixed at 20-30℃for 10min, followed by draining. DMF (100 ml) was added thereto, and after mixing for 5 minutes, the mixture was drained. Washing with DMF was repeated 8 times, 100ml each time, mixing 5min each time, and after the seventh washing, the filtrate was checked with pH paper, which showed that the pH was acceptable at 6.5-7.0.
B. 3.89g of Fmoc-Arg (Pbf) -OH, 2.31g of TBTU and 0.97g of HOBT are weighed in sequence into a clean 1L beaker, 100ml of DMF/DCM solution with the volume ratio of 1:1 is added, the mixture is placed into ice water and stirred and dissolved by a mechanical stirrer at the temperature of 0-10 ℃, after the temperature is constant, 1.49ml of LDIEA is added, the temperature is continuously maintained and stirring and activation are carried out for 5min. Slowly adding the activating solution into a reaction kettle, and mixing for 2 hours at 20-25 ℃. After the reaction, the mixture was drained, 100ml of DMF was added thereto, and after 5 minutes of mixing, the mixture was drained. The DMF washes were repeated 6 times, 100ml each time, and 5min each time mixed. Finally, detecting the obtained product as negative by ninhydrin to obtain the Fmoc-Arg-Gly-Wang resin.
C. According to the deprotection method of the step A and the coupling method of the step B, the residual amino acids or peptide fragments are respectively coupled in sequence according to the sequence of main chain amino acids, namely: fmoc-Gly-OH, fmoc-Arg (Pbf) -OH, fmoc-Val-OH, fmoc-Leu-OH, fmoc-Trp (Boc) -OH, fmoc-Ala-OH, fmoc-Ile-OH, fmoc-Phe-OH, fmoc-Glu (OtBu) -OH, fmoc-Lys (AEEA-AEEA-gamma-Glu (OtBu) -Octadeceioic) -OH, fmoc-Ala-OH, fmoc-Gln (Trt) -OH, fmoc-Gly-OH, fmoc-Glu (OtBu) -OH obtained in example 7 coupling of Fmoc-Glu (OtBu) -OH, fmoc-Leu-OH, fmoc-Tyr (tBu) -OH, fmoc-Ser (tBu) -OH, fmoc-Val-OH, fmoc-Asp (OtBu) -OH, fmoc-Ser (tBu) -OH, fmoc-Thr (tBu) -OH, fmoc-Gly-Thr (tBu) -Phe-OH obtained in example 4, and Fmoc-His (Trt) -Aib-Glu (OtBu) -OH obtained in example 3. After the coupling is completed, the reaction mixture is washed with dichloromethane for 5 times, 100ml each time; after washing, methanol is used for washing twice, and 100ml of methanol is used for each time; washing with dichloromethane for 2 times, each time with 100ml; finally, the resin was washed 3 times with 100ml of alcohol until the resin was sufficiently dispersed. The resin was dried in a vacuum oven at 20-30 ℃ for 4h to constant weight (twice weighing in succession, error lower than 1%). 26.91g of Somam Lu Taitai resin are obtained. The HPLC chromatogram is similar to fig. 1.
EXAMPLE 11 preparation of Sodamantane spermidine
The crude product of the somalundum obtained in the example 8 is dissolved in dilute ammonia water, the pH value of the crude solution of the somalundum is regulated to 8.0-8.5 by phosphoric acid, and the solution of the somalundum is obtained by filtering. Performing HPLC linear gradient elution by taking octalkyl bonded silica gel as a stationary phase and ammonium chloride and acetonitrile as flowing relative to the crude peptide solution of the somalundum, collecting a somalundum fraction, and removing part of acetonitrile by rotary evaporation by using a rotary evaporator to obtain a primary purified solution of the somalundum. The primary purification solution of the somalundum takes octaalkyl bonding silica gel as a stationary phase, potassium dihydrogen phosphate aqueous solution of which the pH is regulated by phosphoric acid, acetonitrile and isopropanol mixed solvent as a mobile phase are subjected to HPLC linear elution, a somalundum fraction is collected, a rotary evaporator is used for rotary evaporation to remove part of acetonitrile, and the secondary purification solution of the somalundum is obtained. The secondary purification liquid of the somalundum takes octaalkyl bonding silica gel as a stationary phase, ammonium bicarbonate aqueous solution and acetonitrile as a mobile phase to carry out HPLC linear elution, the somalundum fraction is collected, the acetonitrile and most of water are removed by rotary evaporation through rotary evaporator, 4.86g of the somalundum peptide refined peptide is obtained by freeze drying, the HPLC purity is 99.75%, the HPLC chromatogram is shown in figure 2, and the purification yield is 68.24%.
Claims (4)
1. A solid phase synthesis method of a somalupeptide is characterized in that: respectively synthesizing R1-His (R2) -Aib-Glu (OR 3) -OH fragment and R4-Gly-Thr (R5) -Phe-OH fragment, using for synthesizing the somalupeptide resin, and obtaining the somalupeptide through cleavage and purification, wherein
R1 is selected from the group consisting of Fmoc, dde, alloc, boc, trt, dmb, mmt, mtt,
r2 is selected from the group consisting of Fmoc, dde, alloc, boc, trt, dmb, mmt, mtt,
r3 is selected from tBu and Bzl,
r4 is selected from Fmoc,
r5 is selected from tBu and Bzl.
2. The solid phase synthesis method of somalupeptide of claim 1, wherein: the R1 is selected from the group consisting of: boc or Fmoc, R2 is selected from: trt or Boc, R3 is selected from tBu, R4 is selected from Fmoc, and R5 is selected from tBu.
3. The solid phase synthesis method of somalupeptide of claim 2, wherein: r1 is Boc, R2 is Trt, R3 is tBu, R4 is Fmoc, and R5 is tBu.
4. The method of claim 1, wherein in the solid phase synthesis of somalundin, S20 is: fmoc-Lys (AEEA-AEEA-gamma-Glu (OtBu) -Octadecananioic) -OH.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010393322.2A CN113637064B (en) | 2020-05-11 | 2020-05-11 | Synthetic method of somalupeptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010393322.2A CN113637064B (en) | 2020-05-11 | 2020-05-11 | Synthetic method of somalupeptide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113637064A CN113637064A (en) | 2021-11-12 |
CN113637064B true CN113637064B (en) | 2023-11-28 |
Family
ID=78415426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010393322.2A Active CN113637064B (en) | 2020-05-11 | 2020-05-11 | Synthetic method of somalupeptide |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113637064B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116710462A (en) | 2021-01-20 | 2023-09-05 | 维京治疗公司 | Compositions and methods for treating metabolic disorders and liver diseases |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016046753A1 (en) * | 2014-09-23 | 2016-03-31 | Novetide, Ltd. | Synthesis of glp-1 peptides |
WO2018032843A1 (en) * | 2016-08-19 | 2018-02-22 | 深圳市健元医药科技有限公司 | Method for synthesizing semaglutide |
CN108034004A (en) * | 2017-12-29 | 2018-05-15 | 江苏诺泰澳赛诺生物制药股份有限公司 | A kind of synthetic method of Suo Malu peptides |
CN108059666A (en) * | 2018-02-10 | 2018-05-22 | 润辉生物技术(威海)有限公司 | A kind of method that solid-liquid combination prepares Suo Malu peptides |
CN108359006A (en) * | 2018-05-25 | 2018-08-03 | 扬子江药业集团四川海蓉药业有限公司 | A kind of preparation method of Suo Malu peptides |
CN109180801A (en) * | 2018-11-01 | 2019-01-11 | 山东汉泰生物科技有限公司 | A method of synthesis Suo Malu peptide |
-
2020
- 2020-05-11 CN CN202010393322.2A patent/CN113637064B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016046753A1 (en) * | 2014-09-23 | 2016-03-31 | Novetide, Ltd. | Synthesis of glp-1 peptides |
WO2018032843A1 (en) * | 2016-08-19 | 2018-02-22 | 深圳市健元医药科技有限公司 | Method for synthesizing semaglutide |
CN108034004A (en) * | 2017-12-29 | 2018-05-15 | 江苏诺泰澳赛诺生物制药股份有限公司 | A kind of synthetic method of Suo Malu peptides |
CN108059666A (en) * | 2018-02-10 | 2018-05-22 | 润辉生物技术(威海)有限公司 | A kind of method that solid-liquid combination prepares Suo Malu peptides |
CN108359006A (en) * | 2018-05-25 | 2018-08-03 | 扬子江药业集团四川海蓉药业有限公司 | A kind of preparation method of Suo Malu peptides |
CN109180801A (en) * | 2018-11-01 | 2019-01-11 | 山东汉泰生物科技有限公司 | A method of synthesis Suo Malu peptide |
Also Published As
Publication number | Publication date |
---|---|
CN113637064A (en) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108059666B (en) | A kind of method that solid-liquid combination prepares Suo Malu peptides | |
CN113135991B (en) | Method for preparing somaglutide | |
WO2018032521A1 (en) | Method for synthesizing liraglutide | |
CN109180801B (en) | Method for synthesizing Somalutide | |
CN111944039A (en) | Synthetic method of somaglutide | |
CN110372785B (en) | Synthesis method of Somalutide | |
CN112010961B (en) | Solid-liquid synthesis method of somalupeptide | |
CN110317258B (en) | New polypeptide fragment of somaglutide and preparation method thereof | |
CN110922470A (en) | Preparation method of somaglutide | |
US20130030148A1 (en) | Process for the synthesis of (aib8,35)hglp-1(7-36)-nh2 | |
CN112679602B (en) | Solid phase synthesis method of cable Ma Lutai | |
CN113637064B (en) | Synthetic method of somalupeptide | |
CN111748019A (en) | Synthetic method of polypeptide derivative compound | |
CN112125970B (en) | Synthesis method of semaglutide | |
CN108070030B (en) | Preparation method of loxenapeptide and analogue thereof | |
CN115181174A (en) | Preparation method of Tirzepatide | |
CN112028986A (en) | Synthesis method of semaglutide | |
CN116444645A (en) | Preparation method of teicoplanin | |
CN111944038B (en) | Synthetic method of somalupeptide | |
CN111944037B (en) | Synthetic method of somalupeptide | |
CN115677827A (en) | Peptide compounds | |
CN112175067B (en) | Preparation method of teduglutide | |
CN110845600B (en) | Method for preparing liraglutide | |
CN113173987B (en) | Method for synthesizing linatide | |
CN113501871B (en) | Method for preparing darunavagon by combining solid phase with liquid phase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |